Indication
Gastroesophageal reflux disease
Gastroesophageal reflux disease is a chronic gastrointestinal disorder characterized by the retrograde flow of gastric contents into the esophagus and upper aerodigestive tract, producing bothersome symptoms or mucosal injury. Read more about Gastroesophageal reflux disease
617 drugs 233 manufacturers
Drugs that treat it
Common Gastroesophageal reflux disease therapies.
NIZATIDINE
OMEPRAZOLE
ESOMEPRAZOLE MAGNESIUM
ACID REDUCER (famotidine)
DEXLANSOPRAZOLE DR (dexlansoprazole)
FAMOTIDINE
OMEPRAZOLE
OMEPRAZOLE
News & literature
Coming soonRelated codes
Coming soonRelated conditions & guidelines
Coming soonGastroesophageal reflux disease is a chronic gastrointestinal disorder characterized by the retrograde flow of gastric contents into the esophagus and upper aerodigestive tract, producing bothersome symptoms or mucosal injury.
It affects pediatric and adult populations globally and arises primarily from dysfunction of the antireflux barrier, such as transient lower esophageal sphincter relaxations, hypotension of the sphincter, or anatomical disruption from a hiatal hernia.
Clinically, it typically presents with heartburn and acid regurgitation, though extraesophageal manifestations such as chronic cough, laryngitis, or chest pain may also occur.
Prolonged exposure of esophageal tissue to noxious gastric acid and pepsin can lead to complications including erosive esophagitis, peptic strictures, and Barrett esophagus.
- nih.gov
Gastroesophageal reflux disease is a chronic gastrointestinal disorder characterized by the retrograde flow of gastric contents into the esophagus and upper aerodigestive tract, producing bothersome symptoms or mucosal injury
- nih.gov
Gastroesophageal reflux disease is a chronic gastrointestinal disorder characterized by the retrograde flow of gastric contents into the esophagus and upper aerodigestive tract, producing bothersome symptoms or mucosal injury Clinically, it typically presents with heartburn and acid regurgitation, though extraesophageal manifestations such as chronic cough, laryngitis, or chest pain may also occur Prolonged exposure of esophageal tissue to noxious gastric acid and pepsin can lead to complication...
- nih.gov
It affects pediatric and adult populations globally and arises primarily from dysfunction of the antireflux barrier, such as transient lower esophageal sphincter relaxations, hypotension of the sphincter, or anatomical disruption from a hiatal hernia
- nih.gov
It affects pediatric and adult populations globally and arises primarily from dysfunction of the antireflux barrier, such as transient lower esophageal sphincter relaxations, hypotension of the sphincter, or anatomical disruption from a hiatal hernia Prolonged exposure of esophageal tissue to noxious gastric acid and pepsin can lead to complications including erosive esophagitis, peptic strictures, and Barrett esophagus
- nih.gov
It affects pediatric and adult populations globally and arises primarily from dysfunction of the antireflux barrier, such as transient lower esophageal sphincter relaxations, hypotension of the sphincter, or anatomical disruption from a hiatal hernia
- nih.gov
Clinically, it typically presents with heartburn and acid regurgitation, though extraesophageal manifestations such as chronic cough, laryngitis, or chest pain may also occur Prolonged exposure of esophageal tissue to noxious gastric acid and pepsin can lead to complications including erosive esophagitis, peptic strictures, and Barrett esophagus
Personalize your experience
Follow Gastroesophageal reflux disease and get updates as they land.
Already a member? Sign in
Follow an indication and get alerts when its drugs, labels, or guidelines change
Save any drug on this page to your favorites, synced across devices
AI-curated peer-reviewed research, summarized for your specialty
A morning digest of indication-relevant updates, when you want it
Sign in to follow this indication
Following an indication requires a free Physicians Office Resource account.